Loading…
The Federal Trade Commission has moved to block Edwards Lifesciences' purchase of JenaValve Technology and its Trilogy transcatheter heart valve system for treating aortic regurgitation. Edwards plans to continue pursuing the deal, with a final determination expected by the end of March 2026.